Switch theme
Sign up to access all valuation multiples
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.
2012
4
Last FY Revenue n/a
Last FY EBITDA -$1.0M
$3.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, QUIA PHARMA achieved revenue of n/a and an EBITDA of -$1.0M.
QUIA PHARMA expects next 12-month revenue of XXX and NTM EBITDA of XXX
See QUIA PHARMA valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | $47K | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$1.0M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$3.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$3.0M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, QUIA PHARMA's stock price is SEK 0 (or $0).
QUIA PHARMA has current market cap of SEK 14.6M (or $1.5M), and EV of SEK 35.1M (or $3.6M).
See QUIA PHARMA trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.6M | $1.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, QUIA PHARMA has market cap of $1.5M and EV of $3.6M.
QUIA PHARMA's trades at n/a EV/Revenue multiple, and -3.6x EV/EBITDA.
Equity research analysts estimate QUIA PHARMA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
QUIA PHARMA's P/E ratio is not available.
See valuation multiples for QUIA PHARMA and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5M | XXX | $1.5M | XXX | XXX | XXX |
| EV (current) | $3.6M | XXX | $3.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialQUIA PHARMA's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.8M for the same period.
QUIA PHARMA's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
QUIA PHARMA's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for QUIA PHARMA and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
QUIA PHARMA acquired XXX companies to date.
Last acquisition by QUIA PHARMA was XXXXXXXX, XXXXX XXXXX XXXXXX . QUIA PHARMA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was QUIA PHARMA founded? | QUIA PHARMA was founded in 2012. |
| Where is QUIA PHARMA headquartered? | QUIA PHARMA is headquartered in Sweden. |
| How many employees does QUIA PHARMA have? | As of today, QUIA PHARMA has 4 employees. |
| Is QUIA PHARMA publicy listed? | Yes, QUIA PHARMA is a public company listed on STO. |
| What is the stock symbol of QUIA PHARMA? | QUIA PHARMA trades under QUIA ticker. |
| When did QUIA PHARMA go public? | QUIA PHARMA went public in 2005. |
| Who are competitors of QUIA PHARMA? | Similar companies to QUIA PHARMA include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of QUIA PHARMA? | QUIA PHARMA's current market cap is $1.5M |
| Is QUIA PHARMA profitable? | Yes, QUIA PHARMA is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
